scholarly journals Severely impaired terminal erythroid differentiation as an independent prognostic marker in myelodysplastic syndromes

2018 ◽  
Vol 2 (12) ◽  
pp. 1393-1402 ◽  
Author(s):  
Abdullah Mahmood Ali ◽  
Yumin Huang ◽  
Ronald Feitosa Pinheiro ◽  
Fumin Xue ◽  
Jingping Hu ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Prognostic Marker ◽  
Myelodysplastic Syndromes ◽  
Erythroid Differentiation ◽  
Independent Prognostic Factor ◽  
Independent Prognostic Marker ◽  
Key Points ◽  
Terminal Erythroid Differentiation

Key Points TED is defective in patients with MDS. TED is an independent prognostic factor for survival in MDS.

Luspatercept in the treatment of lower-risk myelodysplastic syndromes

2021 ◽  
Author(s):  
Onyee Chan ◽  
Rami S Komrokji
Keyword(s):  
Clinical Trials ◽  
Myelodysplastic Syndromes ◽  
Transforming Growth Factor Beta ◽  
Transforming Growth Factor ◽  
Safety Data ◽  
Erythroid Differentiation ◽  
Fda Approval ◽  
The Us ◽  
Us Fda ◽  
Terminal Erythroid Differentiation

Transforming growth factor beta (TGF-β) signaling pathway is key to hematopoiesis regulation. Increased activation of this pathway contributes to ineffective terminal erythroid differentiation in myelodysplastic syndromes (MDS). Luspatercept is a novel fusion protein that traps TGF-β ligands preventing them from binding to Type II TGF-β receptors, thereby decreasing phosphorylated SMAD2/3 resulting in the downstream effect of promoting erythropoiesis. Seminal clinical trials using luspatercept, PACE-MD and MEDALIST, demonstrated impressive efficacy in the treatment of transfusion-dependent anemia in intermediate risk or lower MDS had led to the US FDA approval for this indication. This review summarizes luspatercept mechanisms of action, efficacy/safety data supporting its use and ongoing clinical trials in MDS.

scholarly journals Quantitative analysis of murine terminal erythroid differentiation in vivo: novel method to study normal and disordered erythropoiesis

Blood ◽  
2013 ◽  
Vol 121 (8) ◽  
pp. e43-e49 ◽  
Author(s):  
Jing Liu ◽  
Jianhua Zhang ◽  
Yelena Ginzburg ◽  
Huihui Li ◽  
Fumin Xue ◽  
...  
Keyword(s):  
Quantitative Analysis ◽  
Reliable Method ◽  
Erythroid Differentiation ◽  
Key Points ◽  
Novel Method ◽  
Terminal Erythroid Differentiation

Key Points The study establishes a reliable method to quantify differentiating mouse erythroblasts and to monitor terminal mouse erythropoiesis in vivo. Quantitative analysis of erythropoiesis of thalassemia mice revealed stage-specific changes in terminal erythroid differentiation.

scholarly journals Global transcriptome analyses of human and murine terminal erythroid differentiation

Blood ◽  
2014 ◽  
Vol 123 (22) ◽  
pp. 3466-3477 ◽  
Author(s):  
Xiuli An ◽  
Vincent P. Schulz ◽  
Jie Li ◽  
Kunlu Wu ◽  
Jing Liu ◽  
...  
Keyword(s):  
Erythroid Differentiation ◽  
Key Points ◽  
Global Transcriptome ◽  
Transcriptome Analyses ◽  
Significant Stage ◽  
Species Specific ◽  
Terminal Erythroid Differentiation

Key Points Transcriptome analyses of human and murine reveal significant stage and species-specific differences across stages of terminal erythroid differentiation. These transcriptomes provide a significant resource for understanding mechanisms of normal and perturbed erythropoiesis.

The level of residual disease based on mutant NPM1 is an independent prognostic factor for relapse and survival in AML

Blood ◽  
2013 ◽  
Vol 122 (1) ◽  
pp. 83-92 ◽  
Author(s):  
Nona Shayegi ◽  
Michael Kramer ◽  
Martin Bornhäuser ◽  
Markus Schaich ◽  
Johannes Schetelig ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Residual Disease ◽  
Disease Free Survival ◽  
Allogeneic Transplantation ◽  
Independent Prognostic Factor ◽  
Rt Pcr ◽  
Free Survival ◽  
Key Points ◽  
Disease Free

Key Points NPM1 RT-PCR levels >1% are associated with poor overall and disease-free survival in AML patients treated with chemotherapy. NPM1 MRD levels >10% are associated with poor overall and disease-free survival in AML patients after allogeneic transplantation.

scholarly journals Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy

Blood ◽  
2016 ◽  
Vol 128 (3) ◽  
pp. 395-404 ◽  
Author(s):  
Carmen Diana Herling ◽  
Marion Klaumünzer ◽  
Cristiano Krings Rocha ◽  
Janine Altmüller ◽  
Holger Thiele ◽  
...  
Keyword(s):  
Prognostic Factor ◽  
Treatment Response ◽  
Independent Prognostic Factor ◽  
Controlled Study ◽  
Key Points ◽  
Prospective Controlled Study ◽  
Impact Outcome

Key Points First prospective, controlled study to identify complex karyotypes as an independent prognostic factor of survival in CLL. First study to show that mutations in KRAS or POT1 impact treatment response and survival after chemoimmunotherapy.

scholarly journals High ΔNp73/TAp73 ratio is associated with poor prognosis in acute promyelocytic leukemia

Blood ◽  
2015 ◽  
Vol 126 (20) ◽  
pp. 2302-2306 ◽  
Author(s):  
Antonio R. Lucena-Araujo ◽  
Haesook T. Kim ◽  
Carolina Thomé ◽  
Rafael H. Jacomo ◽  
Raul A. Melo ◽  
...  
Keyword(s):  
Overall Survival ◽  
Acute Promyelocytic Leukemia ◽  
Prognostic Marker ◽  
Cumulative Incidence ◽  
Poor Prognosis ◽  
Promyelocytic Leukemia ◽  
Expression Ratio ◽  
Independent Prognostic Marker ◽  
Key Points

Key Points High ΔNp73/TAp73 expression ratio is associated with lower overall survival and higher cumulative incidence of relapse in APL. ΔNp73/TAp73 expression ratio is an independent prognostic marker in APL.

scholarly journals Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia

Blood ◽  
2014 ◽  
Vol 123 (25) ◽  
pp. 3864-3872 ◽  
Author(s):  
Rajasekhar N. V. S. Suragani ◽  
Sharon M. Cawley ◽  
Robert Li ◽  
Samantha Wallner ◽  
Mark J. Alexander ◽  
...  
Keyword(s):  
Iron Overload ◽  
Erythroid Differentiation ◽  
Bone Defects ◽  
Ineffective Erythropoiesis ◽  
Activin Receptor ◽  
Key Points ◽  
Terminal Erythroid Differentiation ◽  
Activin Receptor Iib

Key Points Modified ActRIIB ligand trap promotes terminal erythroid differentiation and mitigates ineffective erythropoiesis in murine β-thalassemia. This agent reduces anemia, α-globin aggregates, hemolysis, and disease complications such as iron overload, splenomegaly, and bone defects.

scholarly journals Downregulation of the Wnt inhibitor CXXC5 predicts a better prognosis in acute myeloid leukemia

Blood ◽  
2015 ◽  
Vol 125 (19) ◽  
pp. 2985-2994 ◽  
Author(s):  
Andrea Kühnl ◽  
Peter J. M. Valk ◽  
Mathijs A. Sanders ◽  
Adam Ivey ◽  
Robert K. Hills ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Prognostic Factor ◽  
Tumor Suppressor ◽  
Wnt Signaling ◽  
Myeloid Leukemia ◽  
Independent Prognostic Factor ◽  
Candidate Tumor Suppressor ◽  
Key Points ◽  
Wnt Inhibitor ◽  
Acute Myeloid

Key Points CXXC5 inhibits Wnt signaling and is a candidate tumor suppressor in AML. Low CXXC5 expression is an independent prognostic factor in AML.

Sign in / Sign up

Export Citation Format

Share Document